The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma
- 30 November 1996
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 15 (2) , 279-286
- https://doi.org/10.1016/0731-7085(96)01838-9
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I study of topotecan for pediatric patients with malignant solid tumors.Journal of Clinical Oncology, 1994
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitorAnnals of Oncology, 1993
- DNA topoisomerase I and II as targets for rational design of new anticancer drugsAnnals of Oncology, 1993
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 daysAnti-Cancer Drugs, 1992
- A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some AnaloguesJournal of Pharmaceutical Sciences, 1992
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1990